Key facts
- This page summarizes Michael Rabinowitz's Form 4 filing for ORAMED PHARMACEUTICALS INC. (ORMP).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 04 Jan 2023, 06:24.
Michael Rabinowitz - 03 Jan 2023 Form 4 Insider Report for ORAMED PHARMACEUTICALS INC. (ORMP)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- ORMP
- Reported as of
- 03 Jan 2023
- Net transaction value
- -$167,195
- SEC form
- 4
- Accepted by SEC
- 04 Jan 2023, 06:24:13 UTC
- Prior SEC filing
- 01 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Rabinowitz
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Michael Rabinowitz filed Form 4 for ORAMED PHARMACEUTICALS INC. (ORMP) on 04 Jan 2023.
Change
- Previous filing in this sequence was filed on 01 Aug 2022.
- Current net transaction value: -$167,195.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ORMP
transaction
Common Stock
Sale
- Transaction value
- $18,544
- Shares
- -1,425
- Change %
- -1%
- Price
- $13.01
- Shares after
- 138,043
- Date
- 03 Jan 2023
- Ownership
- Direct
- Footnotes
- F1
ORMP
transaction
Common Stock
Sale
- Transaction value
- $148,651
- Shares
- -11,900
- Change %
- -8.6%
- Price
- $12.49
- Shares after
- 126,143
- Date
- 03 Jan 2023
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 7, 2022.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.01 to $13.15, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the above range.